Lingnuo (Shanghai) Pharmaceutical Technology Co., Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Lingnuo (Shanghai) Pharmaceutical Technology Co., Ltd. - overview
Established
2019
Location
Shanghai, Shanghai, China
Primary Industry
Healthcare IT
About
Based in Shanghai, China and established in 2019, Lingnuo (Shanghai) Pharmaceutical Technology Co. , Ltd. operates as a drug technology developer that focuses on antibody treatment. The company established scientific advisory committee in April 2021.
Zhaozhong Han the founder of the company. The core research team of the company has more than 20 members of its total employees. In December 2024, the firm closed a series A funding. The company provides treatment of severe chronic diseases, such as severe inflammatory disease.
The company focuses on macromolecule delivery technology and selective complement inhibition. The company's product pipeline includes LIN-2001 (recombinant protein), LIN-2002 (AAV gene therapy) and LIN-2003 (recombinant protein). The company's products include best-in-class (BIC) and first-in-class (FIC), such as complement targeted antibodies, recombinant protein drugs. The company’s revenue is generated by providing complement-targeted antibodies and recombinant protein drugs.
Current Investors
Puhua Capital, Shanghai Zhangke Lingyi Investment Management Co., LTD, Tian Rui Feng Nian Private Fund
Primary Industry
Healthcare IT
Sub Industries
Healthcare IT, Chiropractic, Orthopedic & Physical Therapy, Pharmaceutical Research & Development
Website
www.linnopharma.com
Verticals
HealthTech
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.